CN118290403A - 吡唑基-氨基-嘧啶基衍生物的苯甲酰胺及其组合物和方法 - Google Patents

吡唑基-氨基-嘧啶基衍生物的苯甲酰胺及其组合物和方法 Download PDF

Info

Publication number
CN118290403A
CN118290403A CN202410365633.6A CN202410365633A CN118290403A CN 118290403 A CN118290403 A CN 118290403A CN 202410365633 A CN202410365633 A CN 202410365633A CN 118290403 A CN118290403 A CN 118290403A
Authority
CN
China
Prior art keywords
mmol
compound
amino
pyrazol
yield
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410365633.6A
Other languages
English (en)
Chinese (zh)
Inventor
万昭奎
迈克尔·劳伦斯·巴斯克斯
李晓东
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lingke Pharmaceutical Hangzhou Co ltd
Original Assignee
Lingke Pharmaceutical Hangzhou Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lingke Pharmaceutical Hangzhou Co ltd filed Critical Lingke Pharmaceutical Hangzhou Co ltd
Publication of CN118290403A publication Critical patent/CN118290403A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202410365633.6A 2018-12-14 2019-12-16 吡唑基-氨基-嘧啶基衍生物的苯甲酰胺及其组合物和方法 Pending CN118290403A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/CN2018/121165 WO2020118683A1 (en) 2018-12-14 2018-12-14 Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
CNPCT/CN2018/121165 2018-12-14
PCT/CN2019/125552 WO2020119819A1 (en) 2018-12-14 2019-12-16 Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
CN201980076141.2A CN113227074B (zh) 2018-12-14 2019-12-16 吡唑基-氨基-嘧啶基衍生物的苯甲酰胺及其组合物和方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980076141.2A Division CN113227074B (zh) 2018-12-14 2019-12-16 吡唑基-氨基-嘧啶基衍生物的苯甲酰胺及其组合物和方法

Publications (1)

Publication Number Publication Date
CN118290403A true CN118290403A (zh) 2024-07-05

Family

ID=71076270

Family Applications (7)

Application Number Title Priority Date Filing Date
CN202410365633.6A Pending CN118290403A (zh) 2018-12-14 2019-12-16 吡唑基-氨基-嘧啶基衍生物的苯甲酰胺及其组合物和方法
CN202411028128.9A Pending CN118903141A (zh) 2018-12-14 2019-12-16 吡唑基-氨基-嘧啶基衍生物的苯甲酰胺及其组合物和方法
CN202411028131.0A Pending CN118903142A (zh) 2018-12-14 2019-12-16 吡唑基-氨基-嘧啶基衍生物的苯甲酰胺及其组合物和方法
CN202410365639.3A Pending CN118388457A (zh) 2018-12-14 2019-12-16 吡唑基-氨基-嘧啶基衍生物的苯甲酰胺及其组合物和方法
CN202411028139.7A Pending CN119118999A (zh) 2018-12-14 2019-12-16 吡唑基-氨基-嘧啶基衍生物的苯甲酰胺及其组合物和方法
CN202411028121.7A Pending CN118955477A (zh) 2018-12-14 2019-12-16 吡唑基-氨基-嘧啶基衍生物的苯甲酰胺及其组合物和方法
CN201980076141.2A Active CN113227074B (zh) 2018-12-14 2019-12-16 吡唑基-氨基-嘧啶基衍生物的苯甲酰胺及其组合物和方法

Family Applications After (6)

Application Number Title Priority Date Filing Date
CN202411028128.9A Pending CN118903141A (zh) 2018-12-14 2019-12-16 吡唑基-氨基-嘧啶基衍生物的苯甲酰胺及其组合物和方法
CN202411028131.0A Pending CN118903142A (zh) 2018-12-14 2019-12-16 吡唑基-氨基-嘧啶基衍生物的苯甲酰胺及其组合物和方法
CN202410365639.3A Pending CN118388457A (zh) 2018-12-14 2019-12-16 吡唑基-氨基-嘧啶基衍生物的苯甲酰胺及其组合物和方法
CN202411028139.7A Pending CN119118999A (zh) 2018-12-14 2019-12-16 吡唑基-氨基-嘧啶基衍生物的苯甲酰胺及其组合物和方法
CN202411028121.7A Pending CN118955477A (zh) 2018-12-14 2019-12-16 吡唑基-氨基-嘧啶基衍生物的苯甲酰胺及其组合物和方法
CN201980076141.2A Active CN113227074B (zh) 2018-12-14 2019-12-16 吡唑基-氨基-嘧啶基衍生物的苯甲酰胺及其组合物和方法

Country Status (14)

Country Link
US (6) US12421213B2 (cg-RX-API-DMAC7.html)
EP (1) EP3877381A4 (cg-RX-API-DMAC7.html)
JP (3) JP7459094B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250162926A (cg-RX-API-DMAC7.html)
CN (7) CN118290403A (cg-RX-API-DMAC7.html)
AU (3) AU2019399939B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021011147A2 (cg-RX-API-DMAC7.html)
CA (3) CA3230071A1 (cg-RX-API-DMAC7.html)
EA (1) EA202191188A1 (cg-RX-API-DMAC7.html)
IL (3) IL314086B1 (cg-RX-API-DMAC7.html)
MX (3) MX428809B (cg-RX-API-DMAC7.html)
SG (1) SG11202105730TA (cg-RX-API-DMAC7.html)
TW (3) TWI866940B (cg-RX-API-DMAC7.html)
WO (2) WO2020118683A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110627775B (zh) * 2019-10-24 2026-01-30 特科罗生物科技(成都)有限公司 一种小分子化合物
WO2021204159A1 (en) 2020-04-08 2021-10-14 Agios Pharmaceuticals, Inc. Menin inhibitors and methods of use for treating cancer
CN112661655B (zh) * 2020-12-29 2022-02-18 江苏云朴医药新材料科技有限公司 一种1-氨甲基-1-环丙醇类化合物及其合成方法
EP4577535A4 (en) * 2022-08-22 2026-05-20 Hangzhou Highlightll Pharmaceutical Co Ltd JAK1/JAK2/TYK2 INHIBITORS FOR THE TOPICAL TREATMENT OF DERMATOLOGICAL DISEASES
CN115572269B (zh) * 2022-10-08 2024-05-17 广州大学 一种n-三氟异丙基唑类和吲哚化合物及其制备方法
WO2023151724A1 (zh) 2023-05-19 2023-08-17 凌科药业(杭州)有限公司 一种吡唑基-氨基-嘧啶基衍生物的晶型、制备方法及应用
CN116751191B (zh) * 2023-05-19 2025-09-16 凌科药业(杭州)有限公司 一种吡唑基-氨基-嘧啶基衍生物的晶型、制备方法及应用
CN116983312B (zh) * 2023-05-24 2024-07-05 凌科药业(杭州)有限公司 一种药物组合物、外用制剂及其制备方法、应用
WO2024239282A1 (zh) * 2023-05-24 2024-11-28 凌科药业(杭州)有限公司 一种药物组合物、外用制剂及其制备方法、应用
TW202545933A (zh) * 2024-01-26 2025-12-01 大陸商凌科藥業(杭州)有限公司 一種吡唑基-胺基-嘧啶基衍生物的苯甲醯胺的晶型、製備方法及應用
CN120917009A (zh) * 2024-01-26 2025-11-07 凌科药业(杭州)有限公司 一种吡唑基-氨基-嘧啶基衍生物的苯甲酰胺的晶型、制备方法及应用
WO2025256636A1 (zh) * 2024-06-13 2025-12-18 凌科药业(杭州)有限公司 含氮化合物及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
WO2007005643A2 (en) 2005-07-01 2007-01-11 Concert Pharmaceuticals Inc. Novel aryloxyphenylpropanamines
US20070116643A1 (en) 2005-07-01 2007-05-24 Concert Pharmaceuticals Inc. Novel aryloxypropanamines
CN101273024A (zh) 2005-07-29 2008-09-24 康瑟特制药公司 新颖苯并[d][1,3]-二氧杂环戊烯衍生物
CA2616366A1 (en) 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
NZ575548A (en) * 2006-09-18 2011-09-30 Vertex Pharma Heterocyclic inhibitors of c-Met and uses thereof
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
EA020777B1 (ru) * 2007-11-16 2015-01-30 Инсайт Корпорейшн 4-пиразолил-n-арилпиримидин-2-амины, 4-пиразолил-n-пиразолилпиримидин-2-амины и 4-пиразолил-n-пиридилпиримидин-2-амины в качестве ингибиторов киназ janus
AU2011328237A1 (en) * 2010-11-09 2013-05-23 Cellzome Limited Pyridine compounds and aza analogues thereof as TYK2 inhibitors
WO2012143320A1 (en) * 2011-04-18 2012-10-26 Cellzome Limited (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
WO2013014162A1 (en) * 2011-07-28 2013-01-31 Cellzome Limited Heterocyclyl pyrimidine analogues as jak inhibitors
DE102011112978A1 (de) * 2011-09-09 2013-03-14 Merck Patent Gmbh Benzonitrilderivate
KR101361149B1 (ko) * 2012-07-17 2014-02-24 전남대학교산학협력단 가뭄 스트레스 저항성 관련 유전자 및 형질전환 식물체
HRP20181109T1 (hr) * 2013-12-11 2018-11-02 Biogen Ma Inc. Spojevi biarila korisni za liječenje ljudskih bolesti u onkologiji, neurologiji i imunologiji
CN106349224A (zh) * 2016-08-03 2017-01-25 山东大学 一种含有4‑氨基‑(1h)‑吡唑结构的jak激酶抑制剂及其制备方法和应用
CN108864057B (zh) * 2017-05-16 2020-03-31 山东大学 含有4-氨基吡唑结构的jak与hdac双靶点抑制剂及其制备方法和应用
WO2020206588A1 (en) * 2019-04-08 2020-10-15 Lynk Pharmaceuticals Co., Ltd. Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
CN110330484B (zh) * 2019-07-18 2022-08-26 中国药科大学 取代类苯基嘧啶衍生物作为jak激酶抑制剂或其可药用的盐、制备方法及用途
CN110627775B (zh) * 2019-10-24 2026-01-30 特科罗生物科技(成都)有限公司 一种小分子化合物

Also Published As

Publication number Publication date
JP7802105B2 (ja) 2026-01-19
AU2024201125A1 (en) 2024-03-14
AU2024201128A1 (en) 2024-03-14
TW202039474A (zh) 2020-11-01
MX2024005744A (es) 2024-05-28
BR112021011147A2 (pt) 2021-08-31
CN118903142A (zh) 2024-11-08
CN118388457A (zh) 2024-07-26
MX2024005747A (es) 2024-05-28
IL314084A (en) 2024-09-01
TWI889396B (zh) 2025-07-01
IL283968A (en) 2021-07-29
MX428808B (es) 2025-11-13
AU2024201128B2 (en) 2025-03-06
US20230416235A1 (en) 2023-12-28
CN113227074A (zh) 2021-08-06
US20250115586A1 (en) 2025-04-10
US12030870B2 (en) 2024-07-09
JP7459094B2 (ja) 2024-04-01
JP2022510925A (ja) 2022-01-28
EP3877381A4 (en) 2022-08-24
US11981663B2 (en) 2024-05-14
AU2019399939A1 (en) 2021-06-24
US20240083881A1 (en) 2024-03-14
KR20210125983A (ko) 2021-10-19
US20220298144A1 (en) 2022-09-22
CN118903141A (zh) 2024-11-08
CN118955477A (zh) 2024-11-15
US12098142B2 (en) 2024-09-24
US12421213B2 (en) 2025-09-23
US20240025882A1 (en) 2024-01-25
CN119118999A (zh) 2024-12-13
TWI866940B (zh) 2024-12-21
IL314086B1 (en) 2026-05-01
IL314084B1 (en) 2026-05-01
US20230002362A1 (en) 2023-01-05
EP3877381A1 (en) 2021-09-15
IL283968B1 (en) 2025-05-01
US12595253B2 (en) 2026-04-07
WO2020118683A1 (en) 2020-06-18
CA3230071A1 (en) 2020-06-18
TW202440558A (zh) 2024-10-16
CA3122872A1 (en) 2020-06-18
JP7802106B2 (ja) 2026-01-19
CA3230060A1 (en) 2020-06-18
EA202191188A1 (ru) 2021-11-29
IL314086A (en) 2024-09-01
MX428809B (es) 2025-11-13
MX2021006866A (es) 2021-11-17
CN113227074B (zh) 2024-08-16
JP2024089673A (ja) 2024-07-03
KR102881668B1 (ko) 2025-11-04
AU2024201125B2 (en) 2025-03-06
TW202440559A (zh) 2024-10-16
TWI889397B (zh) 2025-07-01
IL283968B2 (en) 2025-09-01
WO2020119819A1 (en) 2020-06-18
KR20250162926A (ko) 2025-11-19
AU2019399939B2 (en) 2024-07-11
SG11202105730TA (en) 2021-06-29
JP2024088646A (ja) 2024-07-02

Similar Documents

Publication Publication Date Title
CN113227074B (zh) 吡唑基-氨基-嘧啶基衍生物的苯甲酰胺及其组合物和方法
HK40118201A (en) Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
HK40113562A (en) Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
HK40113561A (en) Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
HK40119082A (en) Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
HK40118199A (en) Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
HK40119081A (en) Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
HK40057223A (en) Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
HK40057223B (en) Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
BR122024013896A2 (pt) Compostos de benzamidas derivados de pirazolil-amino-pirimidinila e seus usos, composição farmacêutica dos mesmos, e forma de dosagem unitária compreendendo a mesma
EA048017B1 (ru) Бензамиды производных пиразолил-амино-пиримидинила, композиции на их основе и способы применения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40113562

Country of ref document: HK

CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: China

Address after: 310018 No. 291 Fucheng Road, Xiaoshan Street, Qiantang District, Hangzhou City, Zhejiang Province Room 5-402

Applicant after: Lingke Pharmaceutical (Zhejiang) Co., Ltd.

Address before: 310018 Zhejiang Province, Hangzhou City, Hangzhou Economic and Technological Development Zone, No. 291 Fucheng Road, 5th floor, 4th floor

Applicant before: Lingke Pharmaceutical (Hangzhou) Co., Ltd.

Country or region before: China